Jenny Gonzalez-Armenta's questions to Uniqure NV (QURE) leadership • Q2 2025
Question
Jenny Gonzalez-Armenta, on for Joseph Schwartz, inquired about the AMT-130 surgical procedure from a patient's perspective, the ideal patient profile for the surgery, and the potential commercial population, including likely early adopters.
Answer
Chief Medical Officer Walid Abi-Saab described the MRI-guided infusion as a "fairly low complexity procedure" for neurosurgeons, with patients typically discharged within 24 hours. CEO Matt Kapusta identified the target population as early manifest Stage 2 and 3 patients, anticipating strong interest due to the absence of other disease-modifying treatments.